Free e-Learning Courseware will Allow Companies To Measure and Improve Readiness for H1N1 - Companies will be able to track, measure and confirm whatemployees know and what they still nee...(nment including Johnson & Johnson Pf...),Health
Navigation Links
Free e-Learning Courseware will Allow Companies To Measure and Improve Readiness for H1N1 - Companies will be able to track, measure and confirm whatemployees know and what they still need to learn
Date:10/27/2009
nment, including Johnson & Johnson, Pfizer, Schering Plough, GE, General Dynamics, McGraw Hill, Prentice Hall, RBC, Manulife, the Public Health Agency of Canada, and both the Canadian and US Departments of Defense. Bluedrop has offices in St. John's, Halifax, Fredericton, Ottawa, Toronto, Calgary, and Washington, DC. More information is available at www.coursepark.com/h1n1 or through the contact below.
SOURCE Bluedrop Performance Learning
'/>"/>
| SOURCE Bluedrop Performance Learning Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Center for Association Resources Launches E-Learning Service
2. NetLearning to Offer American Heart Association e-Learning Courses
3. ShareCourseware.org - Free Lecture Notes and Course Notes Sharing Site Launched
4. Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month
5. Mega Events in September, Including Chicago Event This Sat./Sun., Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month
6. Donation of $15,000 and Hard Work Allows a Family in Need to Move into New Home
7. Connecticut Catholic Conference Wrong to Allow Plan B in Catholic Hospitals
8. Parents can Help Young Superheroes Battle Cavities on Halloween Night
9. Safety Tips for a Fun and Spooky Halloween
10. Diabetes in the Bedroom: Scarier than Halloween?
11. Chocolate Milk: The Official Drink of Halloween
Post Your Comments:
Breaking Medicine News(10 mins):Health News:SCAN Health Plan Arizona Named one of Area's Best Places to Work by the Phoenix Business Journal and BestCompaniesAZ, LLC 2Health News:Definitive study confirms chemo benefit in postmenopausal breast cancer 2Health News:Definitive study confirms chemo benefit in postmenopausal breast cancer 3Health News:UNFPA Honoured With Human Rights Award 2Health News:UNFPA Honoured With Human Rights Award 3Health News:Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting 2Health News:PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management 2Health News:PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management 3Health News:PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management 4
[0] SCAN Health Plan Arizona Named one of Area's Best Places to Work by the Phoenix Business Journal and BestCompaniesAZ, LLC[0] Definitive study confirms chemo benefit in postmenopausal breast cancer[0] UNFPA Honoured With Human Rights Award[1] Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting[1] PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management
Breaking Medicine Technology:ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 1Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 2Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 3NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 1NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 1NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 3NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 4
[0] ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System[0] FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology[0] Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
Other Medicine Technology:Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell 2Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell 3Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell 4Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial,Targeting System's Success in Mouse Model Reported in Cancer Cell 5Protox Announces Positive Clinical Data from Prostate Cancer Study 2Protox Announces Positive Clinical Data from Prostate Cancer Study 3Protox Announces Positive Clinical Data from Prostate Cancer Study 4Protox Announces Positive Clinical Data from Prostate Cancer Study 5
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |